Literature DB >> 33275734

Treatment of relapsed chronic lymphocytic leukemia after venetoclax.

Meghan C Thompson1, Anthony R Mato1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33275734      PMCID： PMC7727510          DOI： 10.1182/hematology.2020000160

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN： 1520-4383


× No keyword cloud information.
  33 in total

1.  Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL.

Authors:  Constantine S Tam; Judith Trotman; Stephen Opat; Jan A Burger; Gavin Cull; David Gottlieb; Rosemary Harrup; Patrick B Johnston; Paula Marlton; Javier Munoz; John F Seymour; David Simpson; Alessandra Tedeschi; Rebecca Elstrom; Yiling Yu; Zhiyu Tang; Lynn Han; Jane Huang; William Novotny; Lai Wang; Andrew W Roberts
Journal:  Blood       Date:  2019-07-24       Impact factor: 22.113

2.  Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.

Authors:  Carol Moreno; Richard Greil; Fatih Demirkan; Alessandra Tedeschi; Bertrand Anz; Loree Larratt; Martin Simkovic; Olga Samoilova; Jan Novak; Dina Ben-Yehuda; Vladimir Strugov; Devinder Gill; John G Gribben; Emily Hsu; Chih-Jian Lih; Cathy Zhou; Fong Clow; Danelle F James; Lori Styles; Ian W Flinn
Journal:  Lancet Oncol       Date:  2018-12-03       Impact factor: 41.316

3.  Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.

Authors:  John C Byrd; Richard R Furman; Steven E Coutre; Jan A Burger; Kristie A Blum; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Yun Shaw; Elizabeth Bilotti; Cathy Zhou; Danelle F James; Susan O'Brien
Journal:  Blood       Date:  2015-02-19       Impact factor: 22.113

4.  Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies.

Authors:  Romain Guièze; Vivian M Liu; Daniel Rosebrock; Alexis A Jourdain; María Hernández-Sánchez; Aina Martinez Zurita; Jing Sun; Elisa Ten Hacken; Kaitlyn Baranowski; Philip A Thompson; Jin-Mi Heo; Zachary Cartun; Ozan Aygün; J Bryan Iorgulescu; Wandi Zhang; Giulia Notarangelo; Dimitri Livitz; Shuqiang Li; Matthew S Davids; Anat Biran; Stacey M Fernandes; Jennifer R Brown; Ana Lako; Zoe B Ciantra; Matthew A Lawlor; Derin B Keskin; Namrata D Udeshi; William G Wierda; Kenneth J Livak; Anthony G Letai; Donna Neuberg; J Wade Harper; Steven A Carr; Federica Piccioni; Christopher J Ott; Ignaty Leshchiner; Cory M Johannessen; John Doench; Vamsi K Mootha; Gad Getz; Catherine J Wu
Journal:  Cancer Cell       Date:  2019-09-19       Impact factor: 31.743

5.  The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL.

Authors:  Ian W Flinn; Peter Hillmen; Marco Montillo; Zsolt Nagy; Árpád Illés; Gabriel Etienne; Julio Delgado; Bryone J Kuss; Constantine S Tam; Zoltán Gasztonyi; Fritz Offner; Scott Lunin; Francesco Bosch; Matthew S Davids; Nicole Lamanna; Ulrich Jaeger; Paolo Ghia; Florence Cymbalista; Craig A Portell; Alan P Skarbnik; Amanda F Cashen; David T Weaver; Virginia M Kelly; Barry Turnbull; Stephan Stilgenbauer
Journal:  Blood       Date:  2018-10-04       Impact factor: 22.113

6.  Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy.

Authors:  Anthony R Mato; Lindsey E Roeker; Ryan Jacobs; Brian T Hill; Nicole Lamanna; Danielle Brander; Mazyar Shadman; Chaitra S Ujjani; Maryam Sarraf Yazdy; Guilherme Fleury Perini; Javier A Pinilla-Ibarz; Jacqueline Barrientos; Alan P Skarbnik; Pallawi Torka; Jeffrey J Pu; John M Pagel; Satyen Gohil; Bita Fakhri; Michael Choi; Catherine C Coombs; Joanna Rhodes; Paul M Barr; Craig A Portell; Helen Parry; Christine A Garcia; Kate J Whitaker; Allison M Winter; Andrea Sitlinger; Sirin Khajavian; Ariel F Grajales-Cruz; Krista M Isaac; Pratik Shah; Othman S Akhtar; Rachael Pocock; Kentson Lam; Timothy J Voorhees; Stephen J Schuster; Thomas D Rodgers; Christopher P Fox; Nicolas Martinez-Calle; Talha Munir; Erica B Bhavsar; Neil Bailey; Jason C Lee; Hanna B Weissbrot; Chadi Nabhan; Julie M Goodfriend; Amber C King; Andrew D Zelenetz; Colleen Dorsey; Kayla Bigelow; Bruce D Cheson; John N Allan; Toby A Eyre
Journal:  Clin Cancer Res       Date:  2020-03-20       Impact factor: 12.531

7.  Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

Authors:  Andrew W Roberts; Matthew S Davids; John M Pagel; Brad S Kahl; Soham D Puvvada; John F Gerecitano; Thomas J Kipps; Mary Ann Anderson; Jennifer R Brown; Lori Gressick; Shekman Wong; Martin Dunbar; Ming Zhu; Monali B Desai; Elisa Cerri; Sari Heitner Enschede; Rod A Humerickhouse; William G Wierda; John F Seymour
Journal:  N Engl J Med       Date:  2015-12-06       Impact factor: 91.245

8.  Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax.

Authors:  Eugen Tausch; Christof Schneider; Sandra Robrecht; Can Zhang; Anna Dolnik; Johannes Bloehdorn; Jasmin Bahlo; Othman Al-Sawaf; Matthias Ritgen; Anna-Maria Fink; Barbara Eichhorst; Karl-Anton Kreuzer; Maneesh Tandon; Kathryn Humphrey; Yanwen Jiang; William Schary; Lars Bullinger; Daniel Mertens; Michele Porro Lurà; Michael Kneba; Hartmut Döhner; Kirsten Fischer; Michael Hallek; Stephan Stilgenbauer
Journal:  Blood       Date:  2020-06-25       Impact factor: 22.113

9.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Authors:  John C Byrd; Richard R Furman; Steven E Coutre; Ian W Flinn; Jan A Burger; Kristie A Blum; Barbara Grant; Jeff P Sharman; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Juthamas Sukbuntherng; Betty Y Chang; Fong Clow; Eric Hedrick; Joseph J Buggy; Danelle F James; Susan O'Brien
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245

10.  Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study.

Authors:  Wei Xu; Shenmiao Yang; Keshu Zhou; Ling Pan; Zengjun Li; Jianfeng Zhou; Sujun Gao; Daobin Zhou; Jianda Hu; Ru Feng; Haiwen Huang; Meng Ji; Haiyi Guo; Jane Huang; William Novotny; Shibao Feng; Jianyong Li
Journal:  J Hematol Oncol       Date:  2020-05-11       Impact factor: 17.388
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.